Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer

Abstract

The mRNA and protein expression of thymidylate synthase (TS), thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) and their relationship with prognosis were investigated. Real-time quantitative RT-PCR (Taqman) was used to detect the mRNA expression of TS, TP and DPD in formalin-fixed and paraffin-embedded 106 samples of epithelial ovarian cancer and 29 normal ovaries. A TATA box-binding protein (TBP) was used as an endogenous reference gene. A relationship between TS, TP, DPD expression and clinicopathologic features was investigated. The protein location and expression of TS, TP and DPD was examined in the same patients by an avidin-biotin-peroxidase immunohistochemistry. TS and TP mRNA expression levels were significantly higher in tumor group than in normal controls, with the average value of TS and TP mRNA being 6.14±0.62 and 0.59±0.06 in tumor tissue, and 0.71±0.14 and 0.16±0.04 in normal tissue, respectively. DPD mRNA expression levels were significantly lower in tumor group (0.11±0.02) than in normal controls (0.38±0.05). There was statistically significant difference in TS and TP mRNA expression levels among different pathological grades and clinical stages (P<0.05), but histological subtype was not significantly associated with TS and TP mRNA expression. DPD gene expression was not significantly associated with any clinicopathological parameters. Immunohistochemistry revealed that TP protein was mainly distributed in nucleus, and TS and DPD mainly in cytoplasm. The protein expression intensity of TS, TP and DPD was coincided with the mRNA expression levels. It was concluded that TS, TP mRNA and protein expression levels were significantly higher in epithelial ovarian cancer, and DPD mRNA and protein expression levels were significantly lower. The expression levels of TS and DPD were related to the patients’ prognosis and survival. Combined gene expression levels of TS, TP and DPD represent a new variable to predict the clinical outcome in ovarian cancer. The association of TS, TP and DPD expression levels with survival suggests an importance of these genes for tumor occurrence and progression.

Keywords

thymidylate synthase / thymidine phosphorylase / dihydropyrimidine dehydrogenase / ovarian cancer

References

[1] CannistraS.A.. Cancer of the ovary. N Engl J Med, 2004, 351(24): 2519-2529

[2] NaoraH., MontellD.J.. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat Rev Cancer, 2005, 5(5): 355-366

[3] DiSaiaP.J., BlossJ.D.. Treatment of ovarian cancer: new strategies. Gynecol Oncol, 2003, 90(2Pt2): S24-S32

[4] ShaoS.L., LiuX.S.. Analysis of prognostic factors of epithelial ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi (Chinese), 2010, 45(2): 132-136

[5] JeungH.C., CheX.F., HaraguchiM., et al.. Thymidine phosphorylase suppresses apoptosis induced by microtubule-interfering agents. Biochem Pharmacol, 2005, 70(1): 13-21

[6] NapieralskiR., OttK., KremerM., et al.. Combined GADD4 5A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res, 2005, 11(8): 3025-3031

[7] GonenM., HummerA., ZervoudakisA., et al.. Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol, 2003, 21(3): 406-412

[8] MizutaniY., WadaH., OgawaO., et al.. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer, 2001, 92(3): 510-518

[9] AllegraC.J., ParrA.L., WoldL.E., et al.. Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol, 2002, 20(7): 1735-1743

[10] HataK., KamikawaT., AraoS., et al.. Expression of the thymidine phosphorylase gene in epithelial ovarian cancer. Br J Cancer, 1999, 79(11–12): 1848-1854

[11] FujiwakaR., HataK., NakayamaK., et al.. Gene expression for dihydropyrimidine dehydrogenase and thymidine phosphorylase influences outcome in epithelial ovarian cancer. J Clin Oncol, 2000, 18(23): 3946-3951

[12] SpechtK., RichterT., MullerU., et al.. Quantitative gene expression analysis in microdissected archival formalin -fixed and paraffin-embedded tumor tissue. Am J Pathol, 2001, 158(2): 419-429

[13] YoshinareK., KubotaT., WatanabeM., et al.. Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: A study of 88 surgical specimens. Cancer Sci, 2003, 94(7): 633-663

[14] FarrugiaD.C., FordH.E.R., CunninghamD., et al.. Thymidylate synthase sxpression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res, 2003, 9(2): 792-801

[15] JakobsenA., NielsenJ.N., GyldenkerneN., et al.. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. J Clin Oncol, 2005, 23(7): 1365-1369

[16] Miszczak-ZaborskaE., Wo’jcik-KrowirandaK., KubiakR., et al.. The activity of thymidine phosphorylase as a new ovarian tumor marker. Gynecol Oncol, 2004, 94(1): 86-92

[17] IltzschM.H., el KonmiM.H., ChaS.. Kinetic studies of thymidine phosphorylase from mouse liver. Biochemistry, 1985, 24(24): 6799-6807

[18] BrownN.S., BicknellR.. Thymidine phosphorylase, 2-deoxy-Dribose and angiogenesis. Biochem J, 1998, 334(pt1): 1-8

[19] CanellakisE.S.. Pyrimidine metabolism-enzymatic pathways of uracil and thymidine degradation. J Biol Chem, 1956, 221(1): 315-322

[20] FinkR.M., FinkK., HendersonR.B.. Beta-amino acid formation by tissue slices incubated with pyrimidines. J Biol Chem, 1953, 201(1): 349-356

[21] SalongaD., DanenbergK.D., JohnsonM., et al.. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res, 2000, 6(4): 1322-1327

[22] KoopmanM., VenderboschS., van TinterenH., et al.. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomized CAIRO study. Eur J Cancer, 2009, 45(11): 1999-2006

[23] TateishiY., TatemotoY., OhnoS., et al.. Combined evaluation of dihydropyrimidine dehydrogenase and thymidine phosphorylate mRNA levels in tumor predicts the histopathological effect of 5-fluorouracil-based chemoradiotherapy. Cancer Lett, 2009, 274(2): 187-193

[24] TsunodaY., SuzukiK., TsunodaA., et al.. Evaluation of 5-fluorouracil related genes in breast cancer to predict the effect of adjuvant therapy with oral fluorouracil derivatives. Oncol Rep, 2010, 23(3): 771-777

[25] JensenS.A., VainerB., SørensenJ.B.. The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil. Int J Cancer, 2007, 120(3): 694-701

[26] SoongR., ShahN., Salto-TellezM., et al.. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol, 2008, 19(5): 915-919